ДИСФУНКЦИЯ ЖИРОВОЙ ТКАНИ ПРИ ПОЛИЭНДОКРИННО-МЕТАБОЛИЧЕСКОМ ОВАРИАЛЬНОМ СИНДРОМЕ: АДИПОКИНЫ, ГЕПАТОКИНЫ И МЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯ

Authors
  • Пирмухамедова Гулноза Нигматовна

    Частная клиника «Nora Medical», Ташкент, Узбекистан

    Author

  • Тожиева Ирода Мирсоли кизи

    Ташкентский Государственный Медицинский Университет, Ташкент, Узбекистан

    Author

Keywords:
Array
Abstract

Полиэндокринно-метаболический овариальный синдром (ПМОС), ранее обозначавшийся как синдром поликистозных яичников (СПКЯ), сочетает репродуктивные и метаболические нарушения. Все больше данных указывает, что метаболический риск определяется не только количеством жировой ткани, но и ее функциональным состоянием. При ПМОС описаны гипертрофия адипоцитов, нарушение адипогенеза, снижение чувствительности к инсулину, изменения липолиза и секреторной активности, в том числе у женщин с нормальным ИМТ. Наиболее изученными адипокинами остаются адипонектин, лептин, резистин и хемерин. Одновременно возрастает интерес к печени как активному участнику метаболических нарушений и к гепатокинам — фетуину-А, FGF-21, селенопротеину P и ANGPTL3. В обзоре рассмотрены основные механизмы взаимосвязи гиперандрогении, инсулинорезистентности, жировой ткани и печени, а также их возможное клиническое значение.

References

Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899–1912.

Behboudi-Gandevani S, Amiri M, Yarandi RB, et al. The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;88(2):169–184.

Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021;106(9):e3369–e3380.

Blouin K, Nadeau M, Perreault M, et al. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf). 2010;72(2):176–188.

Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.

Bril F, Ezeh U, Amiri M, et al. Adipose tissue dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2024;109(1):10–24.

Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631.

Chazenbalk G, Singh P, Irge D, Shah A, Abbott DH, Dumesic DA. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78(9):920–926.

Chazenbalk G, Trivax BS, Yildiz BO, et al. Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-α. J Clin Endocrinol Metab. 2010;95(2):935–942.

Chen YH, Heneidi S, Lee JM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013;62(7):2278–2286.

Dumesic DA, Akopians AL, Madrigal VK, et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab. 2016;101(11):4178–4188.

Dumesic DA, Phan JD, Leung KL, et al. Adipose insulin resistance in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(6):2171–2183.

Ezeh U, Chen IY, Chen YH, Azziz R. Adipocyte insulin resistance in PCOS: relationship with GLUT-4 expression and whole-body glucose disposal and β-cell function. J Clin Endocrinol Metab. 2020;105(7):e2408–e2420.

Ezeh U, Arzumanyan Z, Lizneva D, et al. Alterations in plasma non-esterified fatty acid kinetics and relationship with insulin resistance in polycystic ovary syndrome. Hum Reprod. 2019;34(2):335–344.

Freitas de Medeiros S, Maciel GAR. Relationship between adipose tissue and liver dysfunction in women with polycystic ovary syndrome and metabolic syndrome. Metabolites. 2026;16:393.

Iglesias P. The endocrine role of hepatokines: implications for human health and disease. Front Endocrinol. 2025;16:1663353.

Lin K, Sun X, Wang X, Wang H, Chen X. Circulating adipokine levels in nonobese women with polycystic ovary syndrome and in nonobese control women: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020;11:537809.

Mannerås-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96(2):E304–E311.

Miao X, Alidadipour A, Saed V, et al. Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation. Acta Diabetol. 2024;61:1339–1361.

Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One. 2017;12(11):e0186136.

Schüler-Toprak S, Ortmann O, Buechler C, Treeck O. The complex roles of adipokines in polycystic ovary syndrome and endometriosis. Biomedicines. 2022;10(10):2503.

Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407:1–10.

Zhang Y, Wang Y, Liu J. Friend or foe for obesity: how hepatokines remodel adipose tissues and translational perspective. Genes Dis. 2023;10:825–847.

Cover Image
Downloads
Published
2026-10-09
Section
Articles